Peel Hunt reissued their buy rating on shares of Sinclair Pharma (LON:SPH) in a report published on Monday, March 26th. They currently have a GBX 48 ($0.69) price objective on the specialty pharmaceutical company’s stock.
Separately, Numis Securities reaffirmed a hold rating and issued a GBX 21 ($0.30) price target on shares of Sinclair Pharma in a report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of GBX 46.40 ($0.66).
Shares of LON SPH remained flat at $GBX 18.75 ($0.27) during midday trading on Monday. 22,000 shares of the stock traded hands, compared to its average volume of 764,933. Sinclair Pharma has a 1-year low of GBX 20.50 ($0.29) and a 1-year high of GBX 36.12 ($0.52).
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma and related companies with MarketBeat.com's FREE daily email newsletter.